Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The "exact" year of the next nwbo ASM has not been set.
Haven't heard the term Comanche in this context, but assuming it is yet another euphemism for freeballing, that is of course the only proper way to wear a kilt.
On behalf of Clan Campbell of Argyle, a dress kilt is certainly proper attire for ASM.
You might consider consider accessorizing with a halberd rather than bagpipes
So you are confirming that in 4 months you are not aware of a single independent oncologist who has publicly supported dcvax based on the 5/10 data and subsequent presentations by Liau, Ashkan.
Thank you for making that crystal clear.
Any new independent oncologists you can add to your list supporting dcvax?
In the 4 months since the 5/10 presentation, surely Doctors Liau, Ashkan, Toms, etc must have convinced at least one oncologist not involved with the trial.
No one?
Cook's AAPL had revenues of $387 billion. Bezos and Gates are retired. While Bezos was still working, his salary was $81k.
Pretty poor choice of comps.
Did you consider Warren Buffett @ 373k per year?
For a pre-revenue company, nwbo pays reasonably well in cash. Since there is no proxy this year, the latest is:
https://www.sec.gov/Archives/edgar/data/1072379/000110465921051466/tm212568-1_def14a.htm
which says:
Powers $700k
Goldman $525k
Bosch $475k
It certainly seems like nwbo has enough cash to afford its executives a decent lifestyle in Bethesda.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1072379/000110465921044832/nwbo-20201231x10k.htm
Search (Control-F) for "Total stock-based compensation expense" to find a table with:
Total stock-based compensation expense $51,955 $1,821
where the first number is for 2020, the second for 2019.
nwbo's SEC filings disagree with your statement.
The 2021 10-K recorded $51.9 million in stock-based compensation expense. So those management options clearly do have value, which nwbo quite reasonably calculates using the Black-Scholes model.
Maybe Dr. Ashkan mumbled deliberately.
What if he thinks a publication and partnership are both coming, but doesn't know which is first?
Why choose just one breadcrumb when you could follow both?
No doubt correct. Always look on the bright side of life.
Thank you for sharing that terrific quote. I had not seen it.
Agreed. Queen Elizabeth II was a class act.
Market prices are based on estimates of approval probability, market size, revenues, profits, etc.
If you are now claiming that AF's $300 million market cap rule favors nwbo, that is hysterical turnabout.
Yet you apparently have no problem believing posts about 99% approval. That is not up to your usual standards of logic, because that is clearly not the case. Just look at how many drugs thought to be slam dunks at the FDA have been shot down. There are always things that can go wrong.
Let's be serious. If there was even a 5% chance of approval anywhere, nwbo stock price would be quite a bit higher.
Claims of 99% chance of approval and calling the stock "de-risked" are simply untrue.
ridiculous nonsensical bullshit.
Hoffie, how come your list of doctors never changes?
Is it because no independent oncologists have offered dcvax support in more than 3 months since TLD?
Do you believe that anyone finds Rago (on Bigger's payroll) or Musella (podiatrist) compelling advocates?
Enron, true ups, SEC, ... You left out Cognate, Advent, NASDAQ violations, Swiss approval, etc. etc.
If there were evil forces out to get nwbo (which is total BS repeated endlessly), they could never come up with material as good as the endless flow provided by Linda Powers.
You clearly do not know the Enron story at all if you think it was only a few perople at the top.
For one visit by Wall Street analysts, Enron built a large room into a fake energy trading desk. Every single person involved in building or sitting at the fake screens knew it was a fraud.
There were 21 people criminally convicted, not 1-3.
Have you looked at Advent's website? You can't expect them to list individual clients, but they certainly imply some relationships beyond just nwbo.
https://www.adventbio.uk/
CLIENT PARTNERSHIP PROFILE
Advent aim to provide GMP production facilities and systems which will be adaptable to our clients needs. This gives the capacity for clients to scale-up and improve their ATMP manufacturing capabilities according to their unique product and patient requirements.
Our clients consist of International Pharma, Emerging Biotechnology/Gene and cell therapy companies.
@Kaizenman, thank you for the thoughtful reply. What a nice contrast to the shouting down approach so many others use.
Your point about the distribution and upside truncation is interesting and relevant. I wish we had more data.
The idea of SOC truncating survival is fairly new. Further research on the topic might lead to trials with immunology alone vs SOC rather than (SOC + immunology) vs SOC. Seems like that would be tough to do blinded, so perhaps a case for pre-defined historical controls.
One question for you. In the p3 trial, dcvax had advantages relative to the control trials in high KPS, MGMT methylation, and total tumor resection. Those are all correlated with longer survival. I suspect patients with 2 or 3 of those characteristics are the most likely candidates to be positive outliers (5+ year survival). Any thoughts?
Failed trials that were well run get published all the time. I never said otherwise.
The p3 data is out, and it is thoroughly mediocre.
Maybe that's why no journal wants to publish it, and nwbo can't even be bothered to submit it to a regulator.
And lest you think I'm being too harsh, recall what nwbo said in its press release in July:
"The Company has not to date submitted an application for commercial approval of DCVax-L."
Give me a break. You totally mischaracterize the situation.
In any trial, the treatment is under investigation, not a sure thing. Given the history of GBM trials, it's about as far from a sure thing as possible.
It's SOC vs ( SOC + test treatment)
The true "Gold Standard" would be OS relative to a well-controlled trial's own control group, not comparing to a handful of other trials cherry-picked years after the trial last treated a patient.
Time for perspective!
XBI up 228% over 10 years.
NWBO down 88% over 10 years.
nwbo pretty much sucks compared to its sector.
Remember when the 10-K/A came out.
I said SEC intern with a checklist.
Several folks here thought it had to be lawyers doing deal due diligence.
It is amazing how often the simple logical explanation carries the day, and the convoluted version looks silly in retrospect.
SEC letter to nwbo 6/28. I just noticed this (and the followup acknowledgement) today. Does anyone know if it was there earlier?
https://www.sec.gov/Archives/edgar/data/1072379/000000000022006894/filename1.pdf
This fully explains the latest amendment to the 10-K regarding the consent of the public accounting firm.
I suspect you are correct.
nwbo's most recent quarterly revenue was 477k.
Maybe 2 patients?
So your broad general statement "Debt funding is risky and terrible management for a company like NWBO" was so wrong that you need to add a bunch of qualifiers?
I agree on the C share pricing.
For the rest, you're quoting 6 month numbers instead of quarterly.
10-Q thoughts
Cash 4.8m at quarter end
Revenues 477k.
paid down some debt
Warrant activity was interesting.
23.7m exercised for cash provided a bit over $5m in cash.
28.8m exercised cashless, which includes some options
Of the remaining 153m warrants, 142m are under either block or suspension. Although some unblock as soon as next week. Warrant exercise has been a useful source of cash, so it would be nice to have more detail.
Class "C" Preferred sold at $16 or slightly less.
During July 2022, the Company entered into various Subscription Agreements (the “Series C Subscription Agreements”) with certain investors (the “Series C Investors”). Pursuant to the Series C Subscription Agreements, the Company is issuing to the Series C Investors an aggregate of 299,858 shares of the Company’s Series C Convertible Preferred Stock, par value $0.001 per share (the “Series C Shares”), at a purchase price between $15.75 and $16.00 per share for gross proceeds of approximately $4.7 million. Pursuant to some of the Series C Subscription Agreements, the Company also made approximately $2.0 million partial debt repayment. The Company received approximately $2.7 million net proceeds from the July financing.
bullshit
The idea that NYAS was not intended for shareholders is 100% fiction. It does not fit the facts because nwbo PR'd the NYAS presentation in advance 5/4/22, and also PR'd how to find the results 5/10/22.
https://nwbio.com/presentation-about-phase-3-trial-of-dcvax-l-for-glioblastoma-to-be-made-at-new-york-academy-of-sciences/
https://nwbio.com/presentation-about-phase-3-trial-of-dcvax-l-for-glioblastoma/
You don't understand. dcvax is a platform. It can be used to treat
GBM
all other solid cancers (w/o any need for trials, just take it on faith)
athlete's foot - hence Musella's keen interest
covid
monkeypox
I believe his point is that using MC instead of PPS takes share count out of the equation. Looks at the overall value of the company rather than a varying number of pieces.
Amazing. We agree on something. TLD is out.
What we will never agree on is that there is any significance whatsoever to how it was presented or by whom. You seem to attach great significance to that distinction. I see zero significance, and find the whole argument silly.
"This Phase III trial reached data lock and top line data was recently presented"
https://nwbio.com/northwest-biotherapeutics-announces-presentations-on-dcvax-l-personalized-vaccines-manufacturing-and-scale-up-and-dcvax-l-clinical-program/
That is a definitive statement from nwbo itself. It is a FACT.
The idea that this is somehow artificial or less than "real" TLD is a meaningless ihub fantasy, backed by nothing.